Pharmacokinetic interactions between antiepileptic drugs (AED) and direct oral anticoagulants (DOAC).
Not yet recruiting
- Conditions
- G40.9I48.9Epilepsy, unspecifiedAtrial fibrillation and atrial flutter, unspecified
- Registration Number
- DRKS00029398
- Lead Sponsor
- Charité – Universitätsmedizin Berlin, Klinik für Neurologie, Klinische und Experimentelle Epileptologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
patients with existing comedication of DOAC and AED
- patients taking DOAC with new indication for AED
- patients taking DOAC without AED treatment
- all approved AEDs in monotherapy
- all approved DOACs
Exclusion Criteria
- patients with legal guardianship
- polytherapy of AED
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antiepileptic drug interactions with direct oral anticoagulants in DRKS00029398?
How do antiepileptic drugs affect the pharmacokinetics of DOACs in patients with epilepsy and atrial fibrillation?
What biomarkers can predict antiepileptic drug-DOAC interactions in patients with G40.9 and I48.9 conditions?
What adverse events are associated with concurrent use of AEDs and DOACs in DRKS00029398?
How do AED-DOAC interactions compare to traditional anticoagulant-enzyme inducer interactions in clinical practice?